See more : ABC Taiwan Electronics Corp. (3236.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Radius Health, Inc. (RDUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Radius Health, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Allied Telesis Holdings K.K. (6835.T) Income Statement Analysis – Financial Results
- Dropbox, Inc. (DBX) Income Statement Analysis – Financial Results
- Eco Innovation Group, Inc. (ECOX) Income Statement Analysis – Financial Results
- AxoGen, Inc. (0HKD.L) Income Statement Analysis – Financial Results
- Megaforce Company Limited (3294.TWO) Income Statement Analysis – Financial Results
Radius Health, Inc. (RDUS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://radiuspharm.com
About Radius Health, Inc.
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.88B | 3.49B | 2.76B | 1.71B | 173.32M | 99.24M | 22.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.57B | 3.00B | 2.31B | 1.50B | 16.09M | 8.43M | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 307.71M | 488.07M | 453.19M | 208.62M | 157.23M | 90.81M | 20.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 10.68% | 14.00% | 16.43% | 12.18% | 90.72% | 91.51% | 93.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 134.63M | 159.71M | 116.76M | 99.91M | 83.08M | 107.41M | 68.28M | 45.72M | 60.54M | 54.96M | 36.18M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 144.15M | 152.70M | 184.16M | 186.68M | 77.54M | 30.80M | 13.67M | 6.83M | 9.47M | 5.33M | 46.78K | 31.99K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 43.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 265.93M | 263.26M | 242.46M | 187.88M | 152.70M | 184.16M | 186.68M | 77.54M | 30.80M | 13.67M | 6.83M | 9.47M | 5.33M | 46.78K | 31.99K | 0.00 |
| Other Expenses | -5.56M | -692.00K | -455.00K | -124.00K | 0.00 | 10.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 265.93M | 263.26M | 242.46M | 187.88M | 269.46M | 294.88M | 269.75M | 184.95M | 99.08M | 59.39M | 67.37M | 64.43M | 41.51M | 46.78K | 31.99K | 0.00 |
| Cost & Expenses | 2.84B | 3.26B | 2.55B | 1.69B | 285.55M | 303.30M | 271.09M | 184.95M | 99.08M | 59.39M | 67.37M | 64.43M | 41.51M | 46.78K | 31.99K | 0.00 |
| Interest Income | 0.00 | 0.00 | 75.00K | 1.40M | 3.93M | 5.62M | 3.23M | 2.44M | 1.04M | 94.00K | 30.00K | 64.00K | 27.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.59M | 8.54M | 5.29M | 8.67M | 24.36M | 22.45M | 8.30M | 0.00 | 1.89M | 2.47M | 2.44M | 2.67M | 758.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 89.76M | 75.05M | 58.60M | 58.17M | 2.31M | 2.87M | 1.95M | 586.00K | 176.00K | 77.00K | 27.00K | 44.00K | 40.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | 38.31M | 226.86M | 214.28M | 21.45M | -106.32M | -196.02M | -243.99M | -182.22M | -99.47M | -59.94M | -58.22M | -66.42M | -41.68M | -46.78K | -31.99K | 0.00 |
| EBITDA Ratio | 1.33% | 6.51% | 7.77% | 1.25% | -61.35% | -197.52% | -1,103.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.93M | 225.91M | 213.73M | 6.85M | -112.23M | -204.06M | -248.97M | -184.95M | -99.08M | -59.39M | -67.37M | -64.43M | -41.51M | -46.78K | -31.99K | 0.00 |
| Operating Income Ratio | -0.14% | 6.48% | 7.75% | 0.40% | -64.75% | -205.63% | -1,125.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -51.27M | 401.00K | 2.54M | -14.01M | -20.76M | -17.27M | -5.26M | 2.14M | -2.45M | -3.09M | 6.68M | -4.70M | -236.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -28.08M | 216.68M | 207.99M | -1.94M | -132.99M | -221.34M | -254.24M | -182.80M | -101.53M | -62.48M | -60.69M | -69.13M | -14.63M | -46.78K | 0.00 | 0.00 |
| Income Before Tax Ratio | -0.97% | 6.22% | 7.54% | -0.11% | -76.73% | -223.03% | -1,149.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.75M | 44.60M | 37.94M | 166.00K | 3.60M | 5.18M | 3.03M | 2.14M | -564.00K | -619.00K | 9.12M | -2.03M | 522.00K | 0.00 | 31.99K | 0.00 |
| Net Income | -25.79M | 168.80M | 165.11M | -4.15M | -132.99M | -221.34M | -254.24M | -182.80M | -101.53M | -62.48M | -60.69M | -69.13M | -42.48M | -46.78K | -31.99K | 0.00 |
| Net Income Ratio | -0.89% | 4.84% | 5.99% | -0.24% | -76.73% | -223.03% | -1,149.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.92 | 6.01 | 5.90 | -0.15 | -2.89 | -4.88 | -5.80 | -4.24 | -2.56 | -3.53 | -7.94 | -7.11 | -169.92 | -0.02 | -0.01 | 0.00 |
| EPS Diluted | -0.92 | 5.72 | 5.66 | -0.15 | -2.89 | -4.88 | -5.80 | -4.24 | -2.56 | -3.53 | -7.94 | -7.11 | -24.59 | -0.02 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 28.01M | 28.08M | 27.98M | 27.67M | 46.03M | 45.36M | 43.80M | 43.07M | 39.64M | 17.70M | 7.64M | 9.72M | 249.97K | 2.50M | 2.50M | 2.50M |
| Weighted Avg Shares Out (Dil) | 28.01M | 29.53M | 29.19M | 27.67M | 46.03M | 45.36M | 43.80M | 43.07M | 39.64M | 17.70M | 7.64M | 9.72M | 1.73M | 2.50M | 2.50M | 2.50M |
Radius Health, Inc. Provides Business Update
Radius Health, Inc. (RDUS) CEO Kelly Martin on Q3 2020 Results - Earnings Call Transcript
Radius Health, Inc.'s (RDUS) CEO Kelly Martin on Q3 2020 Results - Earnings Call Transcript
Radius Health, Inc.: Third Quarter 2020 Operating Results
Source: https://incomestatements.info
Category: Stock Reports